Clinical trials: Malignant Melanomas
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Trial name
- NCT00021164
- Testing
- aldesleukin, incomplete Freund's adjuvant, telomerase: 540-548 peptide vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
This is a Phase 2, single-arm study of nivolumab combined with ipilimumab in subjects with previously untreated, unresectable or metastatic uveal melanoma.
- Trial name
- GEM1402 (NCT02626962)
- Testing
- ipilimumab, Nivolumab
- Where
- 10 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Melanoma Stage IV, Melanoma Stage III
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
- Conditions
- Melanoma Stage IV, Melanoma Stage III, Immunotherapy, Toxicity, Drug
- Trial name
- NCT05652673
- Testing
- nivolumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Breast Cancer, Melanoma
A Study of Tumor Imaging With Multispectral Optoacoustic Tomography
Participants in this study will have Multispectral Optoacoustic Tomography/MSOT imaging of both breasts immediately before their ultrasound-guided breast biopsy procedure begins.
- Trial name
- NCT05488483
- Testing
- Multispectral Optoacoustic Tomography Imaging
- Where
- 4 sites in United States, Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess the pharmacokinetic profile of MS-275 in…
- Trial name
- NCT00185302
- Testing
- Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
- Volunteers
- 28 people
- Sponsor
- Bayer
Malignant Melanoma
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received…
- Trial name
- NCT00864253
- Testing
- ABI-007, Dacarbazine
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 529 people
- Sponsor
- Celgene
Advanced Melanoma, Metastatic Melanoma
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in routine systemic treatment.
- Trial name
- NCT03013101
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Malignant Melanoma
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
This randomized, open-label, two period crossover study will evaluate the effect of food on the pharmacokinetics of a single dose of RO5185426 and the efficacy and safety of continuous administration in patients with BRAF V600E…
- Trial name
- NCT01264380
- Testing
- RO5185426
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Melanoma
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
The purpose of this study is to evaluate the safety and potential effectiveness of a new treatment for advanced and recurrent melanoma involving the combination of Ipilimumab and IFN-α2b before surgery and to test for biomarker…
- Trial name
- NCT01608594
- Testing
- administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Diwakar Davar
Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases…
- Trial name
- HAITILS (NCT04812470)
- Testing
- Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Vastra Gotaland Region
Metastatic Melanoma
Long-term Data Collection for Subjects in MDX-010 Studies
The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.
- Trial name
- MDX010-28 (NCT00928031)
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
Objectives: 1. To determine the feasibility of using microdose amounts of near-infrared (NIR) fluorescent contrast agent to image tumor-draining and contralateral lymphatics in melanoma patients prior to standard-of-care sentinel…
- Trial name
- NCT01295931
- Testing
- Indocyanine Green (IC-Green), Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
To evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar®) and pegylated interferon-α-2b (PegIntron®) in patients with malignant melanoma in stage IV.
- Trial name
- SoraPeg (NCT00623402)
- Testing
- Sorafenib, pegylated interferon α-2b
- Where
- 10 sites in Germany
- Volunteers
- 55 people
- Sponsor
- University Hospital Schleswig-Holstein
LGCMN, Large and Giant Congenital Melanocytic Nevi
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
Background: Large and giant congenital melanocytic nevi (LGCMN) are dark birthmarks (moles). They can grow to 8 inches or more across.
- Conditions
- LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1, Solid Tumor
- Trial name
- NCT07891286
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Metastatic Melanoma
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT02857270
- Testing
- LY3214996, Midazolam, Abemaciclib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Melanoma Stage III, Melanoma
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus…
- Trial name
- NCT04013854
- Testing
- nivolumab, Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.